Main menu

Pfizer News & MediaPharmaceutical News Intended for Media Professionals

Welcome to Pfizer’s News & Media Center—designed to give you immediate access to timely and relevant information about our company. In this section you will find information and resources for journalists, including current and archived Pfizer press releases, a full company press kit, and a comprehensive collection of images and videos in our multimedia library.

 

 
May 29, 2015 - Pfizer’s RAPAMUNE® (sirolimus) Becomes First FDA-Approved Treatment for Lymphangioleiomyomatosis (LAM), A Rare Progressive Lung Disease

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved RAPAMUNE® (sirolimus) for the treatment of lymphangioleiomyomatosis (LAM), a rare, progressive disease that affects the lungs, kidneys and the lymphatic system. This is the first approved treatment that helps stabilize lung function in patients with LAM.

 
May 28, 2015 - Pfizer Announces $3 Million Grants Program to Further Clinical Research in Advanced Breast Cancer

Pfizer Inc. today announced the launch of a competitive, peer-reviewed grants program to support clinical research projects investigating IBRANCE® (palbociclib) in advanced breast cancer. The multi-year program, which will award a total of up to $3 million in grants to investigators in the United States, is an extension of Pfizer’s Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) initiative.

 
May 28, 2015 - Pfizer Global Survey Finds Adults with Rheumatoid Arthritis Who Feel Comfortable Speaking Up About Their Concerns Have a More Positive View of Their Health

Pfizer announced initial results of its global survey of more than 3,600 adults with rheumatoid arthritis (RA) in 13 countries. The RA NarRAtive patient survey is the first of its kind to simultaneously evaluate the patient and healthcare professional (HCP) relationship and communication, as well as the patient’s experience and satisfaction with treatment and disease management.

 
May 19, 2015 - Pfizer Invites Public to View and Listen to Webcast of June 2 Conference Call with Analysts to Review Oncology Business and ASCO Data Presentations

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts on Tuesday, June 2, 2015 at 4:30 p.m. EDT. The purpose of the call is to provide an update on Pfizer’s oncology business and to review Pfizer’s ASCO data presentations.

 
May 14, 2015 - Pfizer Receives Request For Additional Information From FTC Regarding Proposed Acquisition Of Hospira

Pfizer Inc. (NYSE:PFE) today announced that it has received a request for additional information from the U.S. Federal Trade Commission (“FTC”) with respect to its previously announced proposed acquisition of Hospira. The request for information from the FTC, often referred to as a “second request,” was anticipated as part of the regulatory process under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR Act”).

Teleconference: Prevenar 13

Pfizer signs long-term agreement to supply Prevenar 13 to world's poorest countries.

Investor Presentations

Access the Pfizer Presentation Archive to view Executive Leadership presentations to shareholders, analysts, and global health care conferences.

Executive Speeches & Commentary

View Executive Leadership speeches on a variety of topics.

 

 

 

Follow us
Pfizer Twitter Community

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

Pfizer Annual Report

Current Stock Price

.
.
%Change . 52 Wk. High .
Day High . 52 Wk. Low .
Day Low . Mkt. Cap(Mil) .
Open .
Prev Close . Symbol .
Vol. . Exchange .

Online Pfizer Press Kit

Our press kit provides information that might help you write stories or simply find out more about Pfizer.